PE20250262A1 - Compuestos heterociclicos sustituidos - Google Patents
Compuestos heterociclicos sustituidosInfo
- Publication number
- PE20250262A1 PE20250262A1 PE2023003027A PE2023003027A PE20250262A1 PE 20250262 A1 PE20250262 A1 PE 20250262A1 PE 2023003027 A PE2023003027 A PE 2023003027A PE 2023003027 A PE2023003027 A PE 2023003027A PE 20250262 A1 PE20250262 A1 PE 20250262A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- compounds
- cycloalkyl
- substituted heterocyclic
- heterocyclic compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188498P | 2021-05-14 | 2021-05-14 | |
| US202263318149P | 2022-03-09 | 2022-03-09 | |
| PCT/US2022/029102 WO2022241171A1 (en) | 2021-05-14 | 2022-05-13 | Substituted heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20250262A1 true PE20250262A1 (es) | 2025-01-29 |
Family
ID=81927926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023003027A PE20250262A1 (es) | 2021-05-14 | 2022-05-13 | Compuestos heterociclicos sustituidos |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11866414B2 (https=) |
| EP (1) | EP4337655A1 (https=) |
| JP (1) | JP2024518554A (https=) |
| KR (1) | KR20240008336A (https=) |
| AU (1) | AU2022271794A1 (https=) |
| CA (1) | CA3217332A1 (https=) |
| CL (1) | CL2023003308A1 (https=) |
| CO (1) | CO2023015226A2 (https=) |
| IL (1) | IL308421A (https=) |
| MX (1) | MX2023013445A (https=) |
| PE (1) | PE20250262A1 (https=) |
| TW (1) | TW202311247A (https=) |
| WO (1) | WO2022241171A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019373203B2 (en) * | 2018-10-30 | 2024-10-24 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
| EP4146205A4 (en) | 2020-05-05 | 2024-05-29 | Nuvalent, Inc. | HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS |
| IL297832A (en) | 2020-05-05 | 2023-01-01 | Nuvalent Inc | Macrocyclic heteroaromatic chemotherapeutic agents |
| US12492184B2 (en) | 2020-12-22 | 2025-12-09 | InventisBio Co., Ltd. | Heteroaryl compounds, preparation methods and uses thereof |
| CA3208361A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
| EP4294806A1 (en) | 2021-02-19 | 2023-12-27 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| AU2022222470A1 (en) | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| BR112023019861A2 (pt) | 2021-03-31 | 2023-11-07 | Xinthera Inc | Inibidores de mk2 e usos dos mesmos |
| US20240317718A1 (en) * | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| KR20240008337A (ko) * | 2021-05-14 | 2024-01-18 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| PE20250262A1 (es) * | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
| US11884650B2 (en) * | 2021-05-14 | 2024-01-30 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| JP2024518791A (ja) * | 2021-05-14 | 2024-05-02 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
| CN115724830A (zh) * | 2021-08-31 | 2023-03-03 | 浙江文达医药科技有限公司 | 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法 |
| TW202320768A (zh) | 2021-10-01 | 2023-06-01 | 美商努法倫特公司 | 雜芳族大環醚化合物之固體形式、醫藥組成物及製備 |
| WO2024044486A1 (en) * | 2022-08-22 | 2024-02-29 | Ajax Therapeutics, Inc. | Jak2 inhibitor compounds |
| CN120152968A (zh) * | 2022-11-08 | 2025-06-13 | 百时美施贵宝公司 | 取代的杂环化合物 |
| CN118812511A (zh) * | 2023-04-21 | 2024-10-22 | 浙江文达医药科技有限公司 | 作为tyk2抑制剂的杂环化合物及合成和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3495358T (lt) * | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| JP7113023B2 (ja) | 2017-03-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法 |
| PE20250262A1 (es) * | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
-
2022
- 2022-05-13 PE PE2023003027A patent/PE20250262A1/es unknown
- 2022-05-13 IL IL308421A patent/IL308421A/en unknown
- 2022-05-13 TW TW111118122A patent/TW202311247A/zh unknown
- 2022-05-13 EP EP22727672.2A patent/EP4337655A1/en active Pending
- 2022-05-13 WO PCT/US2022/029102 patent/WO2022241171A1/en not_active Ceased
- 2022-05-13 CA CA3217332A patent/CA3217332A1/en active Pending
- 2022-05-13 US US17/743,557 patent/US11866414B2/en active Active
- 2022-05-13 JP JP2023570165A patent/JP2024518554A/ja active Pending
- 2022-05-13 AU AU2022271794A patent/AU2022271794A1/en active Pending
- 2022-05-13 KR KR1020237042720A patent/KR20240008336A/ko active Pending
- 2022-05-13 MX MX2023013445A patent/MX2023013445A/es unknown
-
2023
- 2023-11-07 CL CL2023003308A patent/CL2023003308A1/es unknown
- 2023-11-09 CO CONC2023/0015226A patent/CO2023015226A2/es unknown
- 2023-11-30 US US18/524,426 patent/US20240190829A1/en not_active Abandoned
-
2024
- 2024-12-11 US US18/976,869 patent/US20250163004A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023015226A2 (es) | 2023-11-20 |
| BR112023023425A2 (pt) | 2024-01-30 |
| CL2023003308A1 (es) | 2024-04-26 |
| IL308421A (en) | 2024-01-01 |
| TW202311247A (zh) | 2023-03-16 |
| US11866414B2 (en) | 2024-01-09 |
| MX2023013445A (es) | 2023-12-14 |
| KR20240008336A (ko) | 2024-01-18 |
| US20240190829A1 (en) | 2024-06-13 |
| US20220411384A1 (en) | 2022-12-29 |
| EP4337655A1 (en) | 2024-03-20 |
| WO2022241171A1 (en) | 2022-11-17 |
| JP2024518554A (ja) | 2024-05-01 |
| CA3217332A1 (en) | 2022-11-17 |
| AU2022271794A1 (en) | 2024-01-04 |
| US20250163004A1 (en) | 2025-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20250262A1 (es) | Compuestos heterociclicos sustituidos | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| PE20250021A1 (es) | Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8 | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| AR064258A1 (es) | Inhibidores macrociclicos del virus de hepatitis c | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR057810A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica | |
| UY26727A1 (es) | Derivados de tropano útiles en terapia | |
| NI200600257A (es) | Nuevos compuestos. | |
| RU94031155A (ru) | Амидин - производные, способ их получения, их использование в качестве ингибиторов no - синтазы, фармсостав, способ лечения | |
| BG93979A (bg) | Производни на n-(4-пиперидинил)(дихидробензофуран или дихидро-2н-бензопиран)карбоксамид, фармацевтичен състав, който ги съдържа, метод за получаване на производните и приложението им | |
| AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| AR072793A1 (es) | Compuestos de aril isoxazol con actividades antitumorales | |
| EA202191968A1 (ru) | Новые замещенные производные сульфонилмочевины | |
| ATE431345T1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| AR083017A1 (es) | Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol | |
| AR118084A1 (es) | Inhibidores de enzimas | |
| AR037928A1 (es) | Compuesto de 2-oxopirrolidin 3- sulfonamida, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento | |
| AR042910A1 (es) | Compuestos de pirazolopirimidina y procedimiento para preparar el mismo y composiciones farmaceuticas que los contienen | |
| AR049098A1 (es) | Derivados de pirimidina que son antagonistas del receptor vitronectina. procedimiento de obtencion y composiciones farmaceuticas | |
| AR046347A1 (es) | Tiazolidinonas, su preparacion y su uso como medicamentos | |
| UY28688A1 (es) | Derivados de amida | |
| AR041376A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia |